(Q36694465)

15 August 2017

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? (English)

1 reference

15 August 2017

B Gronlund

1

1 reference

15 August 2017

H H Hansen

2

1 reference

15 August 2017

C Høgdall

3

1 reference

15 August 2017

E V S Høgdall

4

1 reference

15 August 2017

S A Engelholm

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

90

1 reference

15 August 2017

2

1 reference

15 August 2017

377-382

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601501

15 August 2017

0 references

cites work

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Role of tumour markers in monitoring epithelial ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Advanced epithelial ovarian cancer: 1998 consensus statements

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

CA 125 half-life in ovarian cancer: a multivariate survival analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

CA 125 in gynecological pathology--a review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Follow-up of the asymptomatic patient with ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Tumor markers in the management of patients with ovarian cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Reporting results of cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Toxicity and response criteria of the Eastern Cooperative Oncology Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409573

Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601501

Use of tumour markers in monitoring the course of ovarian cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601501

Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer

21 January 2018

1 reference

12 December 2020

Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol

1 reference

12 December 2020

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

12 December 2020

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

12 December 2020

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?

1 reference

12 December 2020

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125

1 reference

12 December 2020

Treatment of recurrent ovarian cancer: increasing options--"recurrent" results

1 reference

12 December 2020

Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer

1 reference

12 December 2020

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601501

1 reference

15 August 2017

1 reference

15 August 2017

1 reference